Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy · 2025
Efficacy of initial combination therapy with anti-SARS-CoV-2 antivirals targeting viral clearance in COVID-19 patients with B-cell lymphoma treated with anti-CD20 antibodies: A retrospective single-centre study in Japan.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Maruyama Shuhei, Wada Daiki, Inoue Akira, Kashihara Masami, Shimazaki Junya, Saito Fukuki, Ishii Kazuyoshi, Nakamori Yasushi, Kuwagata Yasuyuki
Аннотация
OBJECTIVES: There is no clear treatment strategy for persistent COVID-19 infection that enables clinicians to effectively achieve viral clearance, determine the optimal time to discontinue treatment, and prevent virus reactivation. This retrospective, single-centre study aimed to analyse the effectiveness of antiviral therapies in COVID-19 patients with B-cell lymphoma receiving anti-CD20 therapy.
METHODS: Conducted at Kansai Medical University Medical Center between January 2022 and October 2024, the study examined the impact of various antiviral regimens and factors on time to viral clearance, defined as SARS-CoV-2 viral load <1 copy/μL by nasopharyngeal swab.
RESULTS: Sixty-seven cases met the inclusion criteria, with 40 having a history of bendamustine use, and 33 with combination antiviral therapy as the initial treatment. A multivariable Cox proportional hazards model revealed combination antiviral therapy as the initial regimen (HR 0.36, 95 % CI 0.20-0.65, p < 0.001) significantly shortened time to viral clearance, while bendamustine use (HR 2.74, 95 % CI 1.53-4.89, p < 0.001) significantly prolonged time to viral clearance.
CONCLUSION: This study showed the potential of early combination antiviral therapy to shorten the time to viral clearance in this high-risk patient population.
METHODS: Conducted at Kansai Medical University Medical Center between January 2022 and October 2024, the study examined the impact of various antiviral regimens and factors on time to viral clearance, defined as SARS-CoV-2 viral load <1 copy/μL by nasopharyngeal swab.
RESULTS: Sixty-seven cases met the inclusion criteria, with 40 having a history of bendamustine use, and 33 with combination antiviral therapy as the initial treatment. A multivariable Cox proportional hazards model revealed combination antiviral therapy as the initial regimen (HR 0.36, 95 % CI 0.20-0.65, p < 0.001) significantly shortened time to viral clearance, while bendamustine use (HR 2.74, 95 % CI 1.53-4.89, p < 0.001) significantly prolonged time to viral clearance.
CONCLUSION: This study showed the potential of early combination antiviral therapy to shorten the time to viral clearance in this high-risk patient population.